Melbourne, Australia — 1 February 2011
Inavir Royalty for December 2010 quarter
Biota Holdings Limited (ASX:BTA) today announced that Daiichi Sankyo have advised
that sales of Inavir were 2.8 billion Japanese Yen in the period to 31 December 2010.
Inavir was launched in Japan on 19 October 2010.
Biota calculates that royalties receivable at 31 December 2010 are $1.16 million, after allowance for specified selling costs and Japanese withholding tax. Under the agreement with Daiichi Sankyo, Biota expects to receive these funds by the end of February.
Inavir is the first drug of a new class of long acting neuraminidase inhibitors (LANIs)
to address the limitation of the current products, which require daily or more frequent
dosing. The new class provides the opportunity to medicate patients on a "one and
done" basis and offers a number of potential benefits. These include that the patient is more likely to use the product properly and as intended and also offers a reduced cost of storage and transport per course, where the product is intended to be stockpiled.
Inavir is Daiichi Sankyo's registered brand for laninamivir octanoate, also previously
known as CS-8958. Inavir is delivered via a Dry Power Inhaler.